GW-3333
| Code | Size | Price |
|---|
| TAR-T27507-5mg | 5mg | £930.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27507-50mg | 50mg | £1,821.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27507-100mg | 100mg | £2,319.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
GW-3333 is an matrix metalloproteinase inhibitor. It is also a tumor necrosis factor-alpha (TNF)-Converting Enzyme (TACE) inhibitor. The efficacy of GW3333 suggests that dual inhibitors of matrix metalloproteinases and TACE may prove therapeutic as antiarthritics.
CAS:
212609-68-2
Formula:
C22H36N4O4
Molecular Weight:
420.554
Purity:
0.98
SMILES:
CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)[C@H](C(C)C)N(O)C=O)C(=O)Nc1ccccn1
References
1. T?th AE, T?th A, Walter FR, Kiss L, Veszelka S, ?zsv?ri B, Pusk?s LG, Heimesaat MM, Dohgu S, Kataoka Y, R?khely G, Deli MA. Compounds blocking methylglyoxal-induced protein modification and brain endothelial injury. Arch Med Res. 2014 Nov;45(8):753-64. doi: 10.1016/j.arcmed.2014.10.009. Epub 2014 Nov 13. PubMed PMID: 25446614.
2. Tippin TK, Hamilton G, Moore L, Beaudet EJ, Jolley S, Brodie TA, Andrews RC, Becherer JD, McDougald DL, Gaul MD, Hoivik DJ, Mellon-Kusibab K, Lehmann J, Kliewer S, Novick S, Laethem R, Zhao Z, LeCluyse EL. CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans. Drug Metab Dispos. 2003 Jul;31(7):870-7. PubMed PMID: 12814963.
3. Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs. 2002 Jul;11(7):1003-6. PubMed PMID: 12084010.
4. Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem. 2001 Nov 22;44(24):4252-67. PubMed PMID: 11708926.